India API Manufacturer To Invest $300 Million In Malaysia Operation
This article was originally published in PharmAsia News
India-based Malladi Drugs and Pharmaceuticals, maker of active pharmaceutical ingredients, plans to set up a $300 million operation in Malaysia. According to Malaysian Biotechnology, a government agency promoting biotech, Malladi is being encouraged to locate in one of the country's biotech hubs. BioTech CEO Mizal Mahmood said the Malaysian branch would offer the entire range for contract manufacturing beginning with API formulation. Malladi plans eventually to expand into services for the contract research sector in Malaysia. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.